Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/003332PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2022/010552 Applicant BIOAPPLICATIONS INC. Inventor SOHN, Eun-Ju
The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
2.WO/2023/002222COMPOSITIONS COMPRISING DOPED SILICON PARTICLES, AND RELATED METHODS
WO 26.01.2023
Int.Class A61K 8/25
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
19containing inorganic ingredients
25Silicon; Compounds thereof
Appl.No PCT/GB2022/051937 Applicant SISAF LTD Inventor SAFFIE-SIEBERT, Roghieh Suzanne
A pharmaceutical composition comprising particles comprising hydrolysable doped silicon and one or more lipids complexed with an active pharmaceutical ingredient, wherein the particles are doped at a level of at least 1 x1016 dopant atoms per cm3. Also related products, methods, and medical uses.
3.WO/2023/002012STAR-SHAPED PASP-OLIGOAMINE DERIVATIVES
WO 26.01.2023
Int.Class C08G 69/24
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
69Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
02Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids
08derived from amino carboxylic acids
14Lactams
24Pyrrolidones or piperidones
Appl.No PCT/EP2022/070604 Applicant POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. Inventor HERRERA MUÑOZ, Lidia
The present disclosure relates to 3-arm star-shaped polycationically charged polymers consisting of a 1,3,5-benzenetricarboxamide related central core and 3 polypeptide backbone arms and its use as carriers for the delivery of active agents, such as nucleic acids.
4.WO/2023/000167AGROBACTERIUM-MEDIATED COTTON GENETIC TRANSFORMATION METHOD
WO 26.01.2023
Int.Class C12N 15/84
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
84Ti-plasmids
Appl.No PCT/CN2021/107336 Applicant INSTITUTE OF COTTON REASERCH OF CAAS Inventor LI, Fuguang
A cotton genetic transformation method. The method comprises using as a genetic transformation receptor the shoot apical meristem at the lower part of the leaf primordium obtained by peeling from soaked mature cotton seeds, under the condition of ultrasonic treatment, infesting the genetic transformation receptor by using recombinant Agrobacterium tumefaciens containing target DNA to obtain a post-infestation explant, and culturing the post-infestation explant to obtain a transgenic cotton plant. The genetic transformation method has the advantages of simple operation, short growth cycle, good repeatability, small genotype limitation, unified and simple transformation method, high transformation efficiency, good genetic stability of the obtained transgenic cotton plant, etc.
5.WO/2023/004172PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION
WO 26.01.2023
Int.Class C12N 1/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
14Fungi ; Culture media therefor
16Yeasts; Culture media therefor
Appl.No PCT/US2022/038095 Applicant CLARA FOODS CO. Inventor HURST, Logan
Provided are systems and methods for production of recombinant proteins in engineered microorganisms while reducing impurities produced in the culture.
6.WO/2023/002223NUCLEIC ACID VECTOR COMPOSITIONS
WO 26.01.2023
Int.Class A61K 47/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
Appl.No PCT/GB2022/051938 Applicant SISAF LTD Inventor SAFFIE-SIEBERT, Roghieh Suzanne
A nucleic acid vector composition comprising: one or more enzymes and/or one or more fragments thereof; a nucleic acid; one or more particles comprising hydrolysable silicon; and one or more lipids. Also related products, medical uses, and methods.
7.WO/2023/002943BIOMARKER FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING EFFECT OF CANCER THERAPEUTIC DRUG ON CANCER PATIENT, AND KIT FOR PREDICTING PROGNOSIS OF CANCER PATIENT
WO 26.01.2023
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
Appl.No PCT/JP2022/027853 Applicant TOHOKU UNIVERSITY Inventor TAKAI Toshiyuki
A biomarker for predicting the prognosis of a cancer patient, said biomarker comprising immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene; a method for predicting the prognosis of a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; a method for predicting the effect of a substance, which inhibits the binding of fibronectin to immunosuppressive receptor LILRB4, as a cancer therapeutic drug on a cancer patient, said method comprising a step for measuring the expression level of immunosuppressive receptor LILRB4 or immunosuppressive receptor LILRB4 gene in a biological sample from the cancer patient; and a kit for predicting the prognosis of a cancer patient, said kit containing a reagent for measuring the expression level of the aforesaid biomarker.
8.WO/2023/004113COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES
WO 26.01.2023
Int.Class A61K 38/46
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
Appl.No PCT/US2022/038010 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor JAMIESON, Catriona
In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-CoV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.
9.WO/2023/004338SYSTEMS AND METHODS FOR REGULATING TARGET GENES
WO 26.01.2023
Int.Class C40B 30/04
CCHEMISTRY; METALLURGY
40COMBINATORIAL TECHNOLOGY
BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
30Methods of screening libraries
04by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
Appl.No PCT/US2022/073920 Applicant EPICRISPR BIOTECHNOLOGIES, INC. Inventor HART, Daniel O.
The disclosure provides compositions, methods, and systems for modulating expression of target genes (e.g., target endogenous genes). Complexes of the disclosure can be useful for bringing one or more heterologous gene effectors into close proximity with a target gene or target gene regulatory sequence, thereby facilitating modulation of an expression or activity level of the target gene. The disclosure provides, for example, compositions, systems, and methods for high throughput screens to identify heterologous gene effector domains and complexes of the effector domains with guide moieties to modulate expression of particular target gene(s). The disclosure also provides complexes identified by systems disclosed herein that can be employed for other purposes, such as research or as therapeutics.
10.WO/2023/004293RECOMBINANT MICROORGANISMS AND USES THEREFOR
WO 26.01.2023
Int.Class C12N 15/74
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Appl.No PCT/US2022/073855 Applicant LANZATECH, INC. Inventor FACKLER, Nicholas, Alexander
The disclosure provides genetically engineered C1-fixing microorganisms capable of producing nanobodies. Additionally, the disclosure provides engineered microorganisms comprising one or more disrupted genes to strategically divert carbon flux away from nonessential or undesirable products towards products and/or co-products of interest. The disclosure enables co-production of useful chemicals from gaseous substrates.